MGX

0.56507.95%
PM

Pamela M. Wapnick

Chief Financial Officer

Ms. Pamela M. Wapnick, MBA., also known as Pam, is Chief Financial Officer of Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) from September 2023. She served as Chief financial Officer at Diality, Inc. (formerly known as EasyDial Inc.). since September 2022 and also served as its Secretary. Ms. Wapnick served as Chief Financial Officer of Capsida Biotherapeutics, Inc. She served as the Chief Financial Officer of True North Therapeutics, Inc. since August 2, 2016 until 2017. Ms. Wapnick has international business and finance experience to True North, served as Vice President of Finance at Amgen Corporation. She joined True North Therapeutics from Amgen Corporation, where she held senior financial management roles from 2007 to 2016, including Vice President of Finance for Research and Development, where she had corporate finance responsibility for Amgen's global R&D activities and Vice President and Treasurer of Amgen, where she had responsibility for global capital planning, capital markets and banking activities. Prior to Amgen, she held senior financial management positions in the automotive industry, including Federal Mogul Corporation, Delphi Corporation and General Motors Corporation. Ms. Wapnick served as Chief Financial Officer of Graybug Vision, Inc. since December 11, 2017 until September 2019, Ms. Wapnick holds a BA in Economics from Wellesley College and an MBA in Finance from Columbia Business School.

Positions